五度妙笔
API商城
数据库AI-STAL 2.0 | 做药人你好，我是AI-STAL
▶ 引言
我是你们的老朋友——那个几年前用“万亿库”三个字搅动江湖的家伙。那时，我站在新药研发的门口，紧张地搓着衣角，怯生生地向你们打了个招呼：“创新生物药你好，我叫万亿库。”
时光飞逝，转眼间，我们已经清修数载。这几年里，我没有停歇，没有止步，每一天我都在“自我进化”，经历了从内到外的蜕变。今天，我带着更强的能力、更全的矩阵、更智慧的大脑，正式与你重逢。
▶ 我是谁
▶ 超级大脑的我
乘着人工智能的东风，我也成功插上AI的翅膀，进化出专属“超级大脑”——这绝非简单的技术叠加，而是AI对靶点挖掘、药物产生、药物优化、药物评价全流程的深度渗透与赋能，让我彻底摆脱“只存分子、难赋价值”的局限，从一座“取之不尽的分子宝库”，真正蜕变为能“精准定位、高效产出、全程护航”的创新生物药源头智能引擎，成功实现了从“随机筛选”到“理性设计”、从“追求数量”到“兼顾质效”的质的跃迁，为每一步研发注入智能底气。
整合基因组学、转录组学、蛋白质组学、代谢组学等多维度数据，联动专属知识图谱，为靶点识别提供全方位、高维度的信息支撑。AI可智能辅助评估靶点的疾病相关性、可成药性、安全性与选择性、创新性与差异化及临床转化潜力等核心标准，通过对海量复杂数据的智能拆解、分析与综合研判，大幅提升靶点选择的效率与准确性，快速筛选出更具临床价值的优质靶点，从源头规避研发风险，为后续研发之路筑牢根基。
依托外部权威数据库与内部海量实战数据，持续训练调优专属大模型，为抗体序列的从头生成奠定坚实基础，以高效计算手段大幅缩短抗体发现周期、优化发现流程。在大模型的精准指导下，可实现抗体序列从头生成，创造出具备全新特性、全新功能的抗体分子；后续通过构建噬菌体展示库，经多轮筛选、体外表达及体内实验严苛验证，最终高效获得符合研发需求的目标抗体，让创新不再受限于天然资源。
AI药物优化全面覆盖人源化改造、亲和力成熟、成药性提升、PK优化等核心维度，以精细化、标准化改造助力分子品质迭代升级。以亲和力成熟改造为例，通过结构模拟、分子对接、丙氨酸扫描、虚拟筛选等全流程智能优化，可精准获得亲和力更优异的分子；人源化改造、成药性提升、PK优化等其他维度，也将沿用类似标准化智能流程，实现全场景、高质量的分子优化，让每一个分子都经得起临床检验。
可灵活通过文库筛选现有优质抗体资源，或从头设计创新型抗体，为药物研发提供多样化、高潜力的起始分子选择。候选抗体需历经亲和力、表位、免疫原性、稳定性、理化性质及药代动力学等多维度智能预测与严苛评价，层层筛选、严格把关，既确保分子的功能稳定性，也守住临床安全性底线，最终高效快速筛选出具备优异特性的潜在药物先导分子（Hit candidates），为后续研发提速增效。
我的“超级大脑”——以AI为核，驱动靶点挖掘、药物产生、优化、评价全链条智能化升级，让每一个分子都承载精准创新的使命，为创新生物药研发注入磅礴智慧动能，真正实现从“分子宝库”到“创新引擎”的蜕变。
▶ 豪华顶配的我
第一大类：全人抗体库：包含万亿全人抗体库、万亿全人半合成抗体库、万亿全人共轻抗体库、全人源鼠免疫抗体库。
第二大类：单域抗体库：包含万亿高等电点单域抗体库、万亿2C单域抗体库、万亿4C单域抗体库、羊驼免疫抗体库。
第三大类：免疫抗体库：包含小鼠免疫抗体库、犬免疫抗体库、兔免疫抗体库。
第四大类：多肽等新型分子库：包含万亿环状多肽库、AC小型蛋白库、酵母展示文库。
截至目前，我已经完成1000多个分子发现项目，成功推动了上百个PCC项目，其中多个项目已进入临床阶段。更重要的是，AI-STAL平台已全面验证了对主流药物分子的开发能力，涵盖：单抗、双抗、多抗、ADC、AOC、抗体与核素偶联药物、PDC、CAR-T免疫细胞疗法……只要你敢想，我就敢陪你闯。
▶ 超大库容的我
十万亿不是终点，未来我将持续升级扩容，不断突破库容边界。
▶ 未来的我
成长不止，创新不息。我于时光中淬炼，在迭代中前行，未来的我，将始终怀揣热忱、步履不停，持续进化、领跑行业，以三大方向为翼，解锁更广阔的创新天地，不负每一份期待与信任。
当前，我已是稳居行业前沿的十万亿级智能超万亿分子库，库容足足是行业主流水平的100倍，用海量分子为创新筑牢根基。未来，我将步履不停、持续突破，不断构建“新型万亿库”，实现分子库从量的积累到质的飞跃，稳步向百万亿级智能超万亿分子库迈进，让每一份创新需求，都能拥有充足的分子底气。
从当下14大核心子库的完备布局，到未来的多元演进，我将持续拓宽分子形态的边界——向万亿多肽库3.0、万亿高等电点单域抗体库2.0、万亿TCR库、万亿长半衰期共同轻链库、万亿长半衰期低免疫性单域抗体库、万亿全模态智能分子库稳步前行，全面覆盖更多创新分子形态，适配各类前沿疗法研发，打破创新局限。
我将持续深化AI赋能，让“超级大脑”更加强劲：实现全流程智能化精准匹配，将筛选速度提升近10倍，让研发效率再获突破；从传统随机库向“理性设计库”“从头生成库”持续演进，依托AI主动筛选最优序列，让每一次筛选都精准高效，彻底摆脱盲目探索的桎梏，重塑创新生物药研发的全新范式。
未来的我，将让优质先导分子数提升上百倍，实现抗原表位“全空间覆盖”，为源头创新筑牢防线、保驾护航；未来的我，将从源头大幅提升后续研发成功率，把新药发现的漫长周期极致缩短，让创新少走弯路；未来的我，将以平台化运营降低边际成本，用标准化服务提升交付效率，为项目管线的任意挑选与高效转化，奠定坚实基础。终有一天，我将彻底破解新药分子产生及筛选的行业痛点，让创新不再艰难。
这一路走来，岁月为证，初心未改。我始终承载着三优生物“让天下没有难做的创新药”的使命，深耕AI-STAL核心技术，以分子之力，破研发之难，让新药研发从“漫长而孤独的马拉松”蜕变为“里程碑式接力赛”，用每一份坚守与创新，为人类健康事业注入源源不断的力量。
亿万分子星海，初心不改，步履不停；前路漫漫，愿与每一位创新药人并肩同行，共赴生物医药的璀璨未来，共筑守护生命的坚实屏障！
AI-STAL 2.0 | Hello Drug Innovators, I’m AI-STAL
▶ Introduction
I’m your old friend — the one who stirred up the industry a few years ago with the phrase “Super-Trillion Library.” Back then, standing at the gateway of innovative biologics discovery, I nervously introduced myself to you:
“Hello innovative biologics world, my name is Super-Trillion Library.”
Time flies. In the blink of an eye, over the past several years, I have undergone a period of focused evolution. Throughout these years, I have never stopped evolving. Every single day, I have undergone continuous self-transformation — inside and out. Today, I return stronger than ever, equipped with more powerful capabilities, a more comprehensive platform matrix, and a smarter brain.
▶ Who Am I
Within our innovation family, I am the eldest sibling. Alongside me are my younger brothers: the second brother, “Sanyou Intelligent New Drug Accelerator,” and the third brother, “Original Innovative Drug Innovation Workshop.” In the future, I will introduce each member of my family to you one by one.
▶ My “Super Brain”
Powered by the rapid advancement of artificial intelligence, I have evolved with AI-driven wings of my own, developing an exclusive “Super Brain.” This is far more than a simple integration of technologies — it represents deep AI empowerment across the entire workflow of target discovery, molecule generation, optimization, and evaluation.
Through this transformation, I have broken free from the traditional limitation of “passively storing molecular diversity without enabling true translational value.” I have evolved from an inexhaustible molecular repository into an intelligent source engine for biologics innovation capable of precise targeting, efficient molecule generation, and end-to-end development support for next-generation biologics.
This marks a fundamental leap:
- From random screening to rational design
- From quantity-driven discovery to quality-and-efficiency-driven innovation
AI now brings intelligence, confidence, and precision to every stage of biologics R&D.
By integrating multidimensional datasets — including genomics, transcriptomics, proteomics, and metabolomics — together with proprietary knowledge graphs, AI-STAL provides comprehensive, high-dimensional support for target identification.
AI intelligently evaluates key parameters such as:
- Disease relevance
- Druggability
- Safety and selectivity
- Innovation and differentiation
- Clinical translational potential
Through intelligent decomposition, analysis, and interpretation of massive datasets, AI significantly improves both the efficiency and accuracy of target selection, enabling rapid identification of high-value clinical targets while minimizing development risks at the source.
Powered by authoritative external databases and extensive proprietary experimental datasets, our dedicated large-scale AI models are continuously trained and optimized to support de novo antibody sequence generation.
This AI-driven approach dramatically shortens antibody discovery timelines and streamlines the discovery process.
Under the guidance of advanced generative models, entirely novel antibody molecules with unprecedented properties and functions can be created from scratch. These sequences are subsequently validated through phage display library construction, iterative screening, recombinant expression, and rigorous in vivo studies, ultimately enabling efficient acquisition of antibodies tailored to specific development needs.
Innovation is no longer constrained by natural resources.
AI-driven optimization comprehensively covers:
- Humanization
- Affinity maturation
- Developability enhancement
- PK optimization
Taking affinity maturation as an example, AI integrates structural simulation, molecular docking, alanine scanning, and virtual screening into a standardized intelligent workflow to precisely identify molecules with superior binding affinity.
The same intelligent optimization principles apply to humanization, developability enhancement, and PK engineering, ensuring high-quality molecular refinement across all scenarios and preparing every molecule for clinical success.
AI-STAL flexibly supports both:
- Screening from existing high-quality antibody resources
- De novo design of innovative antibodies
Candidate antibodies undergo rigorous multidimensional prediction and evaluation, including:
- Affinity
- Epitope characterization
- Immunogenicity
- Stability
- Biophysical properties
- Pharmacokinetics
Through layer-by-layer screening and stringent quality control, AI-STAL ensures both functional robustness and clinical safety, ultimately enabling rapid identification of high-potential lead molecules for downstream development.
My “Super Brain,” powered by AI at its core, drives intelligent transformation across the entire biologics discovery chain — from target discovery to molecule generation, optimization, and evaluation. Every molecule carries the mission of precision innovation, transforming AI-STAL from a molecular repository into a true innovation engine for next-generation biologics discovery.
▶ My Premium Platform Configuration
Over the past few years, nurtured within the passionate ecosystem of Sanyou Biopharmaceuticals, I have continuously expanded and evolved into an even larger and more sophisticated platform.
Today, I consist of four major categories and 14 core sublibraries, forming one of the industry’s most comprehensive biologics discovery platform ecosystems.
Category I: Fully Human Antibody Libraries
Including:
- Super-Trillion Fully Human Ab Lib.
- Super-Trillion Fully Human Semi-Synthetic Ab Lib.
- Super-Trillion Fully Human Common Light Chain Ab Lib.
- Fully Human Mouse Immune Ab Lib.
Category II: Single-Domain Antibody Libraries
Including:
- Optimal-pI sdAb Lib.
- Humanized 2C sdAb Lib.
- Humanized 4C sdAb Lib.
- Alpaca Immune Ab Lib.
Category III: Immune Antibody Libraries
Including:
- Mouse Immune Ab Lib.
- Canine Immune Ab Lib.
- Rabbit Immune Ab Lib.
Category IV: Novel Molecular Libraries Including Peptides
Including:
- Cyclic peptide Lib.
- AC protein Lib.
- Yeast Display Lib.
To date, I have completed more than 1,000 molecular discovery projects and successfully advanced hundreds of PCC programs, several of which have already entered clinical stages.
More importantly, the AI-STAL platform has comprehensively validated its capabilities across mainstream therapeutic modalities, including:
- Monoclonal antibodies
- Bispecific antibodies
- Multispecific antibodies
- ADCs
- AOCs
- Radioimmunoconjugates
- PDCs
- CAR-T cell therapies
If you can envision it, AI-STAL can help bring it to life.
▶ My Massive Capacity
In contrast:
- My fully human antibody libraries exceed 3 trillion
- My single-domain antibody libraries exceed 4 trillion
- My novel molecular and peptide libraries exceed 4 trillion
- My immune antibody libraries approach 1 trillion
Altogether, my total capacity has reached the 10-trillion level (10¹³) — 100 to 1,000 times larger than conventional libraries.
A 10-billion-scale library may yield only dozens of candidate molecules.
A 10-trillion-scale library can theoretically generate thousands — even tens of thousands — of high-quality lead molecules.
For virtually any target, I can provide abundant high-quality molecular starting points, dramatically improving downstream development success rates from the very beginning.
And 10 trillion is not the finish line.
I will continue expanding, upgrading, and redefining the boundaries of molecular diversity.
▶ In the future
Growth never stops. Innovation never ends.
Tempered by time and driven by iteration, I will continue evolving with passion and determination, leading the industry toward broader frontiers of innovation through three strategic directions:
Today, I already stand at the forefront of the industry as a 10-trillion-scale intelligent molecular library platform — approximately 100 times larger than mainstream industry standards.
In the future, I will continue building next-generation super-trillion libraries, achieving not only quantitative expansion but also qualitative transformation, steadily advancing toward the hundred-trillion scale.
Every innovative idea deserves abundant molecular possibilities.
From today’s 14 core sublibraries to future diversified platforms, I will continuously broaden the boundaries of molecular formats, including:
- Super-Trillion Peptide Library 3.0
- Super-Trillion High-pI Single-Domain Antibody Library 2.0
- Super-Trillion TCR Libraries
- Super-Trillion Long Half-Life Common Light Chain Libraries
- Super-Trillion Long Half-Life Low-Immunogenicity Single-Domain Antibody Libraries
- Super-Trillion Fully Modal Intelligent Molecular Libraries
These expansions will comprehensively support emerging therapeutic modalities and eliminate barriers to innovation.
I will continue strengthening AI empowerment to make my “Super Brain” even more powerful.
Future capabilities will include:
- Fully intelligent end-to-end precision matching
- Nearly 10-fold improvements in screening speed
- Continued evolution from traditional random libraries toward rationally designed and de novo generative libraries
AI will proactively identify optimal sequences, making every screening process more precise and efficient while eliminating the inefficiencies of blind exploration.
This will redefine the paradigm of innovative biologics discovery.
The future me will:
- Increase high-quality lead molecule generation by hundreds of times
- Achieve comprehensive coverage of the epitope landscape
- Dramatically improve downstream R&D success rates
- Shorten the lengthy cycle of new drug discovery
- Reduce costly trial-and-error in innovation
- Lower marginal costs through platform-based operations
- Improve delivery efficiency through standardized services
One day, I will fundamentally solve the industry’s long-standing bottlenecks in novel molecule generation and screening — making innovation no longer difficult.
Throughout this journey, my original mission has never changed.
I continue to carry the mission of Sanyou Biopharmaceuticals:
“Empowering the world to create innovative medicines more efficiently.”
By deeply advancing AI-STAL core technologies, we harness the power of molecules to overcome the challenges of drug discovery — transforming new drug development from a “long and lonely marathon” into a “milestone-driven relay race,” continuously fueling global human health through persistence and innovation.
Across the vast ocean of billions of molecules, our original mission remains unchanged, and our journey never stops.
The road ahead is long, and we look forward to walking side by side with every innovator in biopharma — together building a brighter future for biotechnology and a stronger shield for human life and health.
推荐阅读
Click & Go | 结直肠癌的差异化靶点
创新前沿 | OpenClaw化身生物医药智能工匠
Clicklinks | 三优AI-STAL 2.0-14天先导分子发现
浙江大学上海校友会莅临三优生物考察交流
Clicklinks | oneClick+ 人源化应用程序发布
三优大事记 | “荣膺上海市企业技术中心”
“为源头活水” | 企业家科学家共议原创新药研发生态
三优生物郎国竣：让天下没有难做的创新生物药
三优生物十周年庆典暨2026年年会
现场 | “2026中国新药源头创新论坛”
三优生物十年，从智能超万亿分子库到“创新工场”
不用部署模型，也能做蛋白结构预测？
盘点诺奖技术“噬菌体展示”孕育的抗体药物
三优十周年｜平台篇-抗体工程平台
三优十周年｜平台篇-体外药效平台
特应性皮炎：从免疫紊乱到精准靶向的治疗革命
关于三优生物
三优生物是一家以“让天下没有难做的创新药”为使命，致力于透彻解决创新药源头创新问题的生物医药高科技企业。
公司以智能超万亿分子库（AI-STAL）为核心驱动，以智能新药加速器（SAI-DA）为依托，致力于一站式透彻解决创新药各类分子产生和新药研发问题。
公司致力于打造全球顶尖的原创新药创新工场，协同各方共同加速全球创新药的研发进程。
公司总部位于中国上海，在亚洲、北美洲、欧洲等多地建立了业务中心，形成了全球化的业务网络，现有投产及布局的研发及GMP场地20000多平方米。
公司已与全球2000多家药企、生技公司等建立了良好的合作关系，已赋能1200多个新药研发项目；已完成50多个合作研发项目，其中10多个协同研发项目已推至IND及临床研发阶段。
公司已申请170多项发明专利，其中30多项发明专利已获得授权，并获得了国家级高新技术企业、上海市专精特新、ISO9001、ISO27001等10余项资质及体系认证。
推荐阅读
Click & Go | 结直肠癌的差异化靶点
创新前沿 | OpenClaw化身生物医药智能工匠
Clicklinks | 三优AI-STAL 2.0-14天先导分子发现
浙江大学上海校友会莅临三优生物考察交流
Clicklinks | oneClick+ 人源化应用程序发布
三优大事记 | “荣膺上海市企业技术中心”
“为源头活水” | 企业家科学家共议原创新药研发生态
三优生物郎国竣：让天下没有难做的创新生物药
三优生物十周年庆典暨2026年年会
现场 | “2026中国新药源头创新论坛”
三优生物十年，从智能超万亿分子库到“创新工场”
不用部署模型，也能做蛋白结构预测？
盘点诺奖技术“噬菌体展示”孕育的抗体药物
三优十周年｜平台篇-抗体工程平台
三优十周年｜平台篇-体外药效平台
特应性皮炎：从免疫紊乱到精准靶向的治疗革命
关于三优生物
三优生物是一家以“让天下没有难做的创新药”为使命，致力于透彻解决创新药源头创新问题的生物医药高科技企业。
公司以智能超万亿分子库（AI-STAL）为核心驱动，以智能新药加速器（SAI-DA）为依托，致力于一站式透彻解决创新药各类分子产生和新药研发问题。
公司致力于打造全球顶尖的原创新药创新工场，协同各方共同加速全球创新药的研发进程。
公司总部位于中国上海，在亚洲、北美洲、欧洲等多地建立了业务中心，形成了全球化的业务网络，现有投产及布局的研发及GMP场地20000多平方米。
公司已与全球2000多家药企、生技公司等建立了良好的合作关系，已赋能1200多个新药研发项目；已完成50多个合作研发项目，其中10多个协同研发项目已推至IND及临床研发阶段。
公司已申请170多项发明专利，其中30多项发明专利已获得授权，并获得了国家级高新技术企业、上海市专精特新、ISO9001、ISO27001等10余项资质及体系认证。
